ICU Medical, Inc. (ICUI) Income Statement Analysis

See more : Vitesse Energy, Inc. (VTS) Income Statement Analysis – Financial Results

Complete financial analysis of ICU Medical, Inc. (ICUI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ICU Medical, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.

You may be interested

HIVE Blockchain Technologies Ltd. (HIVE.V) Income Statement Analysis – Financial Results
Nyrstar NV (0RH8.L) Income Statement Analysis – Financial Results
Changzhou Shenli Electrical Machine Incorporated Company (603819.SS) Income Statement Analysis – Financial Results
Photonike Capital SA (MLPHO.PA) Income Statement Analysis – Financial Results
Active Health Foods, Inc. (AHFD) Income Statement Analysis – Financial Results

ICU Medical, Inc. (ICUI)

Industry: Medical - Instruments & Supplies

Sector: Healthcare

Website: https://www.icumed.com

About ICU Medical, Inc.

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991
Revenue	2.26B	2.28B	1.32B	1.27B	1.27B	1.40B	1.29B	379.37M	341.67M	309.26M	313.72M	316.87M	302.20M	284.58M	231.51M	204.73M	188.14M	201.61M	157.53M	75.55M	107.35M	87.81M	69.06M	56.19M	47.00M	39.80M	30.40M	24.60M	21.30M	16.50M	11.40M	10.20M	7.50M
Cost of Revenue	1.52B	1.58B	824.82M	809.51M	794.34M	830.01M	866.52M	177.97M	160.87M	157.86M	158.98M	160.36M	159.84M	153.99M	122.70M	114.91M	109.90M	120.93M	88.13M	39.85M	48.44M	36.46M	28.93M	19.18M	16.00M	14.30M	10.70M	8.40M	8.50M	7.70M	3.90M	3.00M	2.20M
Gross Profit	739.87M	697.76M	491.49M	461.50M	471.86M	570.03M	426.10M	201.40M	180.80M	151.40M	154.73M	156.51M	142.35M	130.59M	108.82M	89.82M	78.24M	80.68M	69.40M	35.70M	58.91M	51.34M	40.12M	37.02M	31.00M	25.50M	19.70M	16.20M	12.80M	8.80M	7.50M	7.20M	5.30M
Gross Profit Ratio	32.75%	30.60%	37.34%	36.31%	37.27%	40.72%	32.96%	53.09%	52.92%	48.96%	49.32%	49.39%	47.11%	45.89%	47.00%	43.87%	41.59%	40.02%	44.06%	47.25%	54.87%	58.47%	58.10%	65.88%	65.96%	64.07%	64.80%	65.85%	60.09%	53.33%	65.79%	70.59%	70.67%
Research & Development	85.34M	92.98M	47.50M	42.95M	48.61M	52.87M	51.25M	12.96M	15.71M	18.33M	12.41M	10.63M	8.59M	4.68M	2.65M	4.82M	8.11M	7.66M	4.82M	3.38M	1.76M	1.47M	1.19M	1.48M	1.20M	1.00M	1.30M	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	0.00	0.00	0.00	0.00	276.88M	328.15M	303.95M	89.43M	1.80M	88.94M	90.38M	84.60M	85.29M	76.64M	68.21M	53.61M	45.48M	44.25M	36.99M	26.41M	23.03M	19.87M	16.82M	14.30M	12.50M	12.10M	8.50M	8.20M	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	100.00K	600.00K	200.00K	100.00K	81.42M	100.00K	300.00K	200.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	606.69M	608.35M	302.58M	283.95M	276.98M	328.15M	303.95M	89.43M	83.22M	88.94M	90.38M	84.60M	85.29M	76.64M	68.21M	53.61M	45.48M	44.25M	36.99M	26.41M	23.03M	19.87M	16.82M	14.30M	12.50M	12.10M	8.50M	8.20M	5.60M	3.90M	2.80M	2.30M	1.20M
Other Expenses	25.01M	-5.14M	127.00K	-975.00K	5.74M	1.47M	-2.48M	767.00K	1.13M	755.00K	765.00K	563.00K	0.00	0.00	0.00	0.00	0.00	-2.09M	0.00	0.00	0.00	0.00	0.00	4.61M	3.90M	2.40M	2.10M	2.00M	1.80M	1.10M	500.00K	200.00K	100.00K
Operating Expenses	717.05M	701.33M	350.21M	325.93M	331.33M	381.01M	355.21M	102.38M	98.93M	107.27M	102.78M	95.23M	93.88M	81.31M	70.85M	58.43M	53.60M	49.81M	41.81M	29.79M	24.79M	21.34M	18.00M	20.39M	17.60M	15.50M	11.90M	10.20M	7.40M	5.00M	3.30M	2.50M	1.30M
Cost & Expenses	2.24B	2.28B	1.18B	1.14B	1.13B	1.21B	1.22B	280.36M	259.80M	265.13M	261.77M	255.59M	253.72M	235.30M	193.55M	173.34M	163.49M	170.74M	129.94M	69.64M	73.23M	57.81M	46.94M	39.57M	33.60M	29.80M	22.60M	18.60M	15.90M	12.70M	7.20M	5.50M	3.50M
Interest Income	7.51M	4.43M	2.80M	3.70M	6.80M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	102.73M	66.38M	858.00K	1.75M	549.00K	709.00K	2.05M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	500.00K	0.00	0.00
Depreciation & Amortization	228.77M	258.80M	99.29M	94.85M	85.21M	74.74M	66.57M	19.05M	18.07M	19.45M	19.51M	19.00M	18.29M	17.35M	15.67M	14.22M	11.80M	11.23M	9.70M	8.60M	7.36M	5.29M	5.03M	4.61M	3.90M	2.40M	2.10M	2.00M	1.80M	1.10M	500.00K	200.00K	100.00K
EBITDA	276.61M	191.55M	223.46M	194.09M	200.47M	271.89M	205.54M	118.07M	99.94M	63.58M	72.83M	80.28M	84.72M	65.00M	52.46M	40.91M	27.75M	35.55M	37.29M	5.91M	41.49M	35.29M	27.15M	21.23M	17.30M	12.40M	9.90M	8.00M	7.20M	4.90M	4.70M	4.90M	4.10M
EBITDA Ratio	12.24%	9.93%	10.79%	10.75%	11.72%	13.61%	5.29%	34.98%	33.14%	22.20%	22.78%	25.33%	16.16%	23.37%	22.66%	19.98%	14.75%	17.63%	21.95%	17.12%	37.60%	38.56%	36.44%	34.06%	33.83%	27.64%	28.29%	27.24%	30.52%	26.06%	36.84%	46.08%	92.00%
Operating Income	22.83M	-8.70M	52.38M	41.81M	63.22M	21.61M	-15.08M	82.94M	68.57M	39.04M	51.95M	61.28M	65.22M	49.28M	37.97M	31.38M	24.65M	30.87M	27.60M	5.91M	34.12M	30.00M	22.12M	16.62M	13.40M	10.00M	7.80M	6.00M	5.40M	3.80M	4.20M	4.70M	4.00M
Operating Income Ratio	1.01%	-0.38%	3.98%	3.29%	4.99%	1.54%	-1.17%	21.86%	20.07%	12.62%	16.56%	19.34%	21.58%	17.32%	16.40%	15.33%	13.10%	15.31%	17.52%	7.83%	31.79%	34.17%	32.03%	29.58%	28.51%	25.13%	25.66%	24.39%	25.35%	23.03%	36.84%	46.08%	53.33%
Total Other Income/Expenses	-101.12M	-71.51M	-59.00K	-668.00K	7.35M	-7.38M	64.58M	2.22M	1.13M	755.00K	765.00K	563.00K	1.20M	129.00K	1.18M	4.70M	8.70M	4.46M	2.72M	1.58M	1.12M	1.43M	1.99M	2.10M	1.40M	1.40M	1.40M	1.20M	800.00K	600.00K	-100.00K	100.00K	-2.90M
Income Before Tax	-78.30M	-114.41M	123.19M	97.49M	114.71M	22.37M	51.28M	85.16M	69.70M	39.79M	52.71M	61.84M	66.42M	49.41M	39.15M	36.08M	33.35M	35.34M	30.32M	7.49M	35.25M	31.43M	24.11M	18.72M	14.80M	11.40M	9.20M	7.20M	6.20M	4.40M	4.10M	4.80M	1.10M
Income Before Tax Ratio	-3.47%	-5.02%	9.36%	7.67%	9.06%	1.60%	3.97%	22.45%	20.40%	12.87%	16.80%	19.52%	21.98%	17.36%	16.91%	17.62%	17.72%	17.53%	19.24%	9.92%	32.83%	35.80%	34.91%	33.31%	31.49%	28.64%	30.26%	29.27%	29.11%	26.67%	35.96%	47.06%	14.67%
Income Tax Expense	-48.64M	-40.12M	20.05M	10.62M	13.67M	-6.42M	-17.36M	22.08M	24.71M	13.46M	12.30M	20.56M	21.75M	18.48M	12.59M	11.78M	10.34M	10.24M	10.46M	-109.00K	12.95M	11.75M	8.72M	6.93M	5.40M	4.20M	3.50M	2.50M	2.00M	1.50M	1.10M	800.00K	200.00K
Net Income	-29.66M	-74.29M	103.14M	86.87M	101.04M	28.79M	68.64M	63.08M	44.99M	26.34M	40.42M	41.28M	44.67M	30.93M	26.56M	24.30M	23.08M	25.66M	20.27M	5.00M	22.30M	19.68M	15.39M	11.79M	9.40M	7.20M	5.70M	4.70M	4.20M	2.90M	3.30M	4.90M	3.00M
Net Income Ratio	-1.31%	-3.26%	7.84%	6.83%	7.98%	2.06%	5.31%	16.63%	13.17%	8.52%	12.88%	13.03%	14.78%	10.87%	11.47%	11.87%	12.27%	12.73%	12.87%	6.62%	20.77%	22.42%	22.28%	20.98%	20.00%	18.09%	18.75%	19.11%	19.72%	17.58%	28.95%	48.04%	40.00%
EPS	-1.23	-3.11	4.86	4.16	4.90	1.33	3.50	3.90	2.84	1.72	2.75	2.90	3.23	2.20	1.80	1.72	1.62	1.78	1.47	0.37	1.62	1.43	1.20	0.95	0.77	0.60	0.47	0.36	0.35	0.27	0.32	0.47	0.36
EPS Diluted	-1.23	-3.11	4.74	4.02	4.69	1.33	3.29	3.66	2.73	1.68	2.65	2.80	3.15	2.16	1.77	1.67	1.51	1.64	1.35	0.33	1.48	1.28	1.06	0.87	0.72	0.57	0.47	0.36	0.35	0.27	0.31	0.47	0.36
Weighted Avg Shares Out	24.09M	23.87M	21.21M	20.91M	20.63M	21.60M	19.61M	16.17M	15.85M	15.28M	14.69M	14.22M	13.84M	13.61M	14.72M	14.14M	14.28M	14.41M	13.81M	13.69M	13.75M	13.79M	12.84M	12.50M	12.23M	11.98M	11.92M	13.26M	11.88M	10.60M	10.31M	10.49M	8.33M
Weighted Avg Shares Out (Dil)	24.09M	23.87M	21.78M	21.59M	21.55M	21.60M	20.86M	17.25M	16.50M	15.65M	15.27M	14.73M	14.16M	13.86M	14.98M	14.56M	15.27M	15.60M	15.04M	14.96M	15.05M	15.35M	14.45M	13.59M	13.04M	12.63M	12.04M	13.26M	12.11M	10.87M	10.76M	10.49M	8.33M

ICU Medical Inc. (ICUI) Q3 2024 Earnings Call Transcript

November 12, 2024seekingalpha.com

ICU Medical Inc. (NASDAQ:ICUI ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants John Mills - ICR Vivek Jain - Chief Executive Officer and Chairman Brian Bonnell - Chief Financial Officer Conference Call Participants Brett...

ICU Medical (ICUI) Tops Q3 Earnings and Revenue Estimates

November 12, 2024zacks.com

ICU Medical (ICUI) came out with quarterly earnings of $1.59 per share, beating the Zacks Consensus Estimate of $1.25 per share. This compares to earnings of $1.57 per share a year ago.

ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc., a Subsidiary of Otsuka Holdings Co. Ltd., Announce Creation of a Joint Venture to Bolster IV Solutions Manufacturing and Innovation in North America

November 12, 2024prnewswire.com

The partnership creates one of the largest global IV solutions manufacturing networks with combined production of an estimated 1.4 billion annual units and aims to bring additional supply chain resiliency and new innovation to the North American IV solutions market....

ICU Medical to Participate at the UBS Global Healthcare Conference

November 6, 2024globenewswire.com

SAN CLEMENTE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the UBS Global Healthcare Conference being held in...

ICU Medical (ICUI) Expected to Beat Earnings Estimates: Should You Buy?

October 28, 2024zacks.com

ICU Medical (ICUI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ICU Medical Announces Time of Third Quarter 2024 Earnings Conference Call

October 28, 2024globenewswire.com

SAN CLEMENTE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2024 earnings release and conference call.